Es que como ministro o trabajador publico no se debería aceptar ningun regalo “personal”. A ver cuando regulan eso eldiario.es/opinion/tribuna-…

They saved some of the best for last @ASCO. Talks today on advanced breast cancer were excellent. Particularly important were the discussions by Meredith Regan @DanaFarber and Matt Goetz @MayoClinic. Both explored how to THINK about trials and data, and how to best use drugs.

IZABRIGHT-Breast01 Trial is ongoing, recruiting in Europe. First line TNBC Patients ineligible for immunotherapy. Impressive drug profile in my short experience.

Perhaps the most important breast cancer discussion this year at ASCO. A brilliant analysis of PFS2 and its meaning (or lack thereof) in advanced breast cancer. Required viewing for all clinical investigators.

These days at #ASCO26, data from the Phase III FLAMINGO-01 trial, in which @GEICAM is participating alongside @GreenwichLS, were presented. 🆕 Preliminary injection site reaction data comparing vaccination over time in GLSI-100 treated non-HLA-A*02 patients showed a significant increase in immune response. Future studies may explore the use of immune responses to assess: correlation of DTH to ISRs, immunogenicity of GLSI-100 by specific HLA type, timing of boosters to sustain immunity, clinical site performance, and the discontinuation of treatment for non-responders. 🔝 GEICAM is represented on the Steering Committee of this study by Dr. Miguel Martín, and our Clinical Operations Executive Director, Gema Sanz, joined the Greenwich LifeSciences, team for the poster presentation. #ASCO26 📍 @ASCO @ASCOPost @oncofir We are pleased to share the poster, along with full information on these data, for all those who may be interested: ⤵️ investor.greenwichlifescienc…

#ASCO26 abst 1064 CAPTURE showed that in post-CDK4/6 PIK3CA-mutant HR /HER2− MBC, alpelisib fulvestrant did not beat capecitabine. PFS: 7.4 vs 9.4 months; ORR: 24% vs 50%. In patients with visceral disease, the picture was even more in favor of capecitabine. The presence of a biomarker alone does not define the right treatment sequence. Beating capecitabine is not that easy!!! I wonder how capivasertib fulvestrant would have performed here?

Alongside #ASCO26, the new ESMO metastatic breast cancer guidelines have just been published in @Annals_Oncology Congrats to all co-authors, and a special mention to @myESMO mentor @E_de_Azambuja for this well-deserved recognition! 👏🏼 @OncoAlert Link: annalsofoncology.org/article…

👏 Y, justo antes de irnos a #ASCO26 📍, os compartimos una buenísima noticia que se acaba de publicar en el European Journal of Cancer (@ElsevierConnect Oncology). 🔬 @GEICAM aporta nuevos datos traslacionales del ensayo clínico fase III GEICAM/2013-02 PEARL, un estudio promovido por nuestro Grupo en colaboración con @Biovica, y cuyos autores principales son los doctores Miguel Martín y Ángel Guerrero-Zotano (@AngelZotano), que refuerzan el valor de DiviTum® TKa como #biomarcador líquido para monitorizar la actividad tumoral y la respuesta al tratamiento en #cáncerdemama metastásico. 🧪 La actividad circulante de la timidina quinasa 1A (#TK1A) se perfila como un potente indicador de la evolución del cáncer de mama #metastásico HR /HER2-. 🧬 Esta enzima, vinculada a la proliferación celular, desempeña un papel esencial en la síntesis del #ADN, un proceso clave para el crecimiento tumoral. 📝 Podéis leer el artículo aquí: ➡️ geicam.org/wp-content/upload…

🚀 Nos hace mucha ilusión haber colaborado en este estudio pionero, por su inmensa relevancia científica y por todo lo que aporta a la comprensión de la experiencia real de las personas con #cáncerdemamametastásico y de sus cuidadores/as. 🤝 El trabajo, que recoge los resultados de un estudio #etnográfico (desarrollado por @gileadsciences España y Portugal, con el asesoramiento científico de @geicam_ 🧬), ha tenido como objetivo ir más allá de los hallazgos clínicos para comprender mejor los desafíos emocionales, sociales y prácticos que se afrontan a lo largo de la enfermedad 🧠⬇️

🌍 @GEICAM is pleased to share its participation in the IARC@60 International Scientific Conference: “Cancer Research into Action”, taking place in Lyon (France), from today until Thursday, a landmark event that will bring together global experts in #cancerresearch at the headquarters of the @IARCWHO 📍 🧬 GEICAM will participate through its collaboration in the #CONFLUENCE Project, the largest multi-ancestry GWAS in #breastcancer to date coordinated by @theNCI 🤝 (400,000 breast cancer cases, 1,600,000 controls, across 62 countries and 300 studies of which, three come from GEICAM: GEICAM 2017/07 EMBARCAM (415 patients), epiGEICAM (865 patients and 834 healthy controls) and the GEICAM 2016/04_Male Breast Cancer Registry (181 patients and 109 healthy controls). 🗣️ Today, 19th of May, at the Mutational Epidemiology for Cancer Prevention Session, Montserrat García-Closas, co-lead of the CONFLUENCE Project will present results from this global effort 🧪: the identification of 477 breast #cancer susceptibility loci, including 238 new loci that highlight new candidate genes, improve how much genetic risk we can explain, and help us better understand breast cancer biology 🔬 Ongoing work will expand this to different populations, sexes and subtypes with new insights on improving risk prediction across ancestries. 🙌 We are proud to contribute biological samples and clinical data to this landmark initiative and to take part in a conference dedicated to transforming cancer research into real-world action 🚀 🔗 More information about the #ConfluenceProject can be found here: ➡️ dceg.cancer.gov/research/can…

💡 Great discussions and meaningful insights emerged from #ESMOBreast26 🚀 Among the highlights for our team was the presentation of this study, not only for its scientific significance, but also for its direct relevance to the lives of patients and caregivers 👇 🔬➡️ We presented findings from an #ethnographic study examining the real-world experiences of patients living with metastatic breast cancer and their #caregivers in Spain. 🤝 Conducted by @GileadSciences España y Portugal with scientific guidance from @GEICAM, the study extends beyond traditional clinical endpoints to characterize the emotional, social, and practical challenges experienced across the disease trajectory. 📋 Drawing on interviews and ethnographic questionnaires completed by 31 #patients and 10 caregivers, the study shows that needs change across disease stages, from the initial impact of diagnosis to long-term management and end-of-life care 🧠 The findings also highlight underrecognized dimensions of the patient experience, including body image, sexuality, and the psychological burden associated with #metastatic disease. 🎯 The results indicate that patient experiences differ by #breastcancer subtype, underscoring the need for more personalized and comprehensive models of care. 💟🧬 Overall, the study reinforces the importance of integrating psychosocial support, stronger communication strategies, and patient-centered resources into #oncology care to address unmet needs that extend beyond medical treatment alone. 🧪 We leave this year’s congress with a strong sense of progress and shared learning, and we look forward to advancing this work through continued research and collaboration 🙌 We are eager to see the next steps in this field.

🔬 Kicking off at #ESMOBreast26! 🧪 Supporting research in HER2-positive metastatic breast cancer. ➡️ The GEICAM/2020-08 TrasTUCAN study, a phase II academic clinical trial exploring new treatment combinations in a highly pretreated patient population. 🔎 The study, led by Dr. Yolanda Jerez, first author and medical oncologist at Hospital General Universitario Gregorio Marañón, as well as one of the Principal Investigators of the study together with Dr. Isabel Álvarez, also a medical oncologist at Hospital Universitario de Donostia, 💊 evaluated the combination of trastuzumab, tucatinib and oral vinorelbine in patients with locally advanced unresectable or #metastatic HER2-positive #breastcancer who had received multiple prior lines of therapy. 💡 At the doses tested, side effects were more frequent and more severe than expected. The main safety concern was severe neutropenia (a marked drop in white blood cells), which increased infection risk and led to early study termination. Treatment activity was modest, in line with what is commonly seen in heavily pretreated populations. ✅ Despite these limitations, the findings provide valuable insights for future #research, highlighting the complexity of developing new combinations after multiple treatment lines and the importance of careful dose selection and early-phase study design. 👏 We are very proud to present these results at #ESMOBC26, as they reflect the value of academic, independent research in advancing knowledge even when studies do not progress as initially expected. Each step helps refine future strategies and improve patient care. #bcsm #CancerResearch #oncology #BreastCancerResearch

ESMO BREAST 2026 GEICAM#. intranet.geicam.org/GEICAM_M…

🙌 #ESMOBreast26: Welcome to your international, multidisciplinary meeting, to explore the most up-to-date science in breast cancer, collaborate with global experts to share real-world experiences and help us build the future of breast cancer care. 🔗 ow.ly/7KRO50YRJeR #esmomeetings

Ya hay la excusa para favorecer a la privada. Que pena. Osakidetza ofrecerá operarse en la privada a los 1.800 vascos que llevan más de medio año en lsita de espera | El Diario Vasco diariovasco.com/sociedad/sal…

🧵 You’re reading trials WRONG (most of us are) If you’ve ever changed practice based on an abstract… This might make you rethink that decision 👇 Follow the thread #OncoTwitter #MedTwitter @OncoAlert @myesmo @esmo_open @asco @EricTopol @oncology_bg Full paper by @oncology_bg in comments below

📄Building on the recent results shared by @GEICAM, we would like to add the transcriptomic analysis from the GEICAM/2013-02 #PEARL study, published in @JCO_ASCO, which provides new insights to further advance the personalization of treatment in HR /HER2− metastatic #breastcancer (MBC). 🔍 A translational study led by Prof. Miguel Martín and Prof. Charles Perou (University of North Carolina, USA) explored gene expression features to identify which patients may benefit more from #palbociclib endocrine therapy (ET) versus #capecitabine (chemotherapy) in tumors resistant to aromatase inhibitors. 🧪 In the setting of ET-resistant HR /HER2- MBC, #PAM50 intrinsic subtype and B-cell-associated tumor gene expression signatures could help predict which patients would benefit more from continuing ET-based treatment with CDK4/6 inhibition or switching to chemotherapy-based treatment. 💡 These results reinforce the value of translational research in advancing precision #oncology and supporting more informed clinical decision-making based on the biological characteristics of each tumor in patients with MBC. ➡️ Access the full publication here: ascopubs.org/doi/full/10.120…

De verdad esto es cierto? En 10 años estaremos realmente mal, enfrentados y sin saber qué esperamos los unos de los otros”: ‘boomers’, X, mileniales y Z hablan sobre la gran brecha generacional | EL PAÍS Semanal | EL PAÍS elpais.com/eps/2026-04-05/en…

We are going to see probably much more cases of ER loss in the near future... are we creating "monster" tumors by our own hands? nature.com/articles/s41467-0…

Guideline Update Provides New Testing & Tx Recx for Pts w/ ER-Positive, HER2-Negative Met Breast Cancer w/ ESR1 Mutations [May 17-18, 2023] @ASCO Daily News - dailynews.ascopubs.org/do/gu… @DrHBurstein et al. @JCO_ASCO ascopubs.org/doi/10.1200/JCO… #bcsm #PrecisionMedicine #LiquidBiopsy